DSpace Repository

Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial

Show simple item record

dc.contributor.author Soto, Alonso
dc.contributor.author Krapp, Fiorella
dc.contributor.author Vargas, Alex
dc.contributor.author Cabrejos, Lucía
dc.contributor.author Argumanis, Enrique
dc.contributor.author García, Patricia L.
dc.contributor.author Altamirano, Karina
dc.contributor.author Montes Delgado, Martin
dc.contributor.author Chacón Uscamaita, Pamela Roxana
dc.contributor.author Garcia Funegra, Patricia Jannet
dc.date.accessioned 2021-06-08T15:46:14Z
dc.date.available 2021-06-08T15:46:14Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/9505
dc.description.abstract Objectives: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay.The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay en_US
dc.language.iso eng
dc.publisher BioMed Central
dc.relation.ispartofseries Trials
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject COVID-19 en_US
dc.subject Randomized controlled trial en_US
dc.subject Mortality en_US
dc.subject Protocol en_US
dc.subject Adverse reactions en_US
dc.subject Convalescent plasma en_US
dc.subject Safety en_US
dc.title Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1186/s13063-021-05189-6
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn 1745-6215


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics